468 reports of this reaction
1.8% of all RITONAVIR 100 MG reports
#10 most reported adverse reaction
ACUTE KIDNEY INJURY is the #10 most commonly reported adverse reaction for RITONAVIR 100 MG, manufactured by Cipla USA Inc.. There are 468 FDA adverse event reports linking RITONAVIR 100 MG to ACUTE KIDNEY INJURY. This represents approximately 1.8% of all 25,519 adverse event reports for this drug.
Patients taking RITONAVIR 100 MG who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a less commonly reported adverse event for RITONAVIR 100 MG, but still significant enough to appear in the safety profile.
In addition to acute kidney injury, the following adverse reactions have been reported for RITONAVIR 100 MG:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 468 FDA reports for RITONAVIR 100 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 1.8% of all adverse event reports for RITONAVIR 100 MG, making it a notable side effect.
If you experience acute kidney injury while taking RITONAVIR 100 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.